UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044445
Receipt number R000050430
Scientific Title Effects of amino acids-enriched food on Achilles tendon discomfort in healthy adults who habitually exercise
Date of disclosure of the study information 2023/04/01
Last modified on 2021/05/10 16:58:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of amino acids-enriched food on Achilles tendon discomfort in healthy adults who habitually exercise

Acronym

Effects of amino acids-enriched food on Achilles tendon discomfort

Scientific Title

Effects of amino acids-enriched food on Achilles tendon discomfort in healthy adults who habitually exercise

Scientific Title:Acronym

Effects of amino acids-enriched food on Achilles tendon discomfort

Region

Japan


Condition

Condition

Healthy adult

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effects of amino acids-enriched food on Achilles tendon discomfort

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Visual Analogue Scale

Key secondary outcomes

TNF-alpha


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Amino acids(4 g, once a day, for 2 weeks)

Interventions/Control_2

Placebo(4 g, once a day, for 2 weeks)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Male and female aged 20 or higher and less than 60 years old.
2. Individuals who have discomfort in Achilles tendon and do not show blood vessel infiltration into Achilles tendon evaluated by an ultrasonography.
3. Individuals who have discomfort in Achilles tendon during exercise or the day after exercise
4. Individuals who exercise more than 2 times a week.
5. Individuals who can make self-judgment and voluntarily provides written informed consent.

Key exclusion criteria

1. Individuals who had a surgery or local injections within one year.
2. Individuals who are in need of a treatment for Achilles tendon, judged by the principal investigator.
3. Individuals who have received a surgery for Achilles tendon in the past.
4. Individuals who are under medications which may affect Achilles tendon such as poultice, ointment or painkiller.
5. Individuals who have severe chronic diseases (hepatic, cardiovascular, respiratory, endocrine, and metabolic disorders)
6. Individuals who are impossible to stop taking supplements or functional foods which may affect Achilles tendon during this study.
7. Indivicuals who take amino acid -related medicines such as LIVACT, AminolebanEN and Hepan ED.
8. Individuals who regularly take amino acid/protein supplements.
9. Individuals who have amino acid metabolism disorders.
10. Individuals who are pregnant, lactating or have these plans.
11. Individuals who received more than 200 mL of blood collection within 12 weeks from the screening test.
12. Individuals who have participated in a study using other food intake or medicines, and cosmetics within one month retrospectively from the time of obtaining consent, or who are participating in other examinations during this study participation.
13. Individuals who are judged as unsuitable for the study by the investigator for the other reasons.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Naoya
Middle name
Last name Sekiguchi

Organization

Urayasu Sekiguchi Clinic

Division name

Director

Zip code

279-0004

Address

5-17-27, Urayasu-shi, Nekozane, Chiba-ken, Japan

TEL

047-306-3557

Email

scfira@royal.ocn.ne.jp


Public contact

Name of contact person

1st name Yoshika
Middle name
Last name Komori

Organization

KSO Corporation

Division name

Sales Department

Zip code

105-0023

Address

Shibaura OMODAKA Bldg. 7F, 1-9-7 Shibaura, Minato-ku, Tokyo,Japan

TEL

03-3452-7733

Homepage URL


Email

eigyou27@kso.co.jp


Sponsor or person

Institute

KSO corporation

Institute

Department

Personal name



Funding Source

Organization

Ajinomoto Co.,Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical Committee of Nihonbashi Cardiology Clinic

Address

Kyodo Bldg. #201, 13 - 4 Nihonbashi Kodenmacho, Chuo-ku, Tokyo

Tel

03-5641-4133

Email

niho-jimucho@well-sleep.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2021 Year 05 Month 26 Day

Date of IRB

2021 Year 05 Month 26 Day

Anticipated trial start date

2021 Year 08 Month 14 Day

Last follow-up date

2021 Year 09 Month 26 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 06 Month 05 Day

Last modified on

2021 Year 05 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050430


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name